« Return to News | CROs/Service Providers

WCCT Global acquires OC Clinical Trials and Consulting

Wednesday, September 25, 2013 12:28 PM

WCCT Global, an Orange County, Calif.-based CRO, has acquired OC Clinical Trials and Consulting, an early stage ophthalmology and cosmetology research practice.

The acquisition provides WCCT Global with expanded early phase capabilities in its ophthalmology center in cornea and external disease, uveitis, vitreoretinal diseases, glaucoma, neuro-ophthlamology, oculoplastics and pediatric ophthalmic conditions such as Strabismus and Amblyopia.

Dr. Michael A. Sheety, WCCTG’s medical and surgery director of ophthalmology and aesthetics, said, “The new team brings more than 75 combined years of clinical and research experience in ophthalmology and aesthetics.”

WCCT now owns and operates five sites, including two Clinical Pharmacology Units (CPUs) with more than 180 beds. WCCT’s ophthalmic patient database has grown ten-fold with patients of varying ages and demographics. Additionally, with an ophthalmology and optometry referral network of more than 20 facilities in southern California, WCCT now has direct access to more than 40,000 ophthalmology and optometry patients. In the cosmetology and aesthetics space, WCCT’s network has grown to more than 45 physicians throughout southern California.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.